MAGE-1 (Target for Cancer Immunotherapy) Mouse Monoclonal Antibody

Recognizes a protein of 42-46kDa, identified as MAGE-1. This MAb does not cross-react with other members of MAGE-family. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.

[melanoma-associated antigen 1; Melanoma-associated antigen 1; melanoma-associated antigen 1; MAGE family member A1; Antigen MZ2-E; Cancer/testis antigen 1.1; CT1.1; MAGE-1 antigen]